Global Cord Blood Corporation (CO) Fundamental Analysis & Valuation

NYSE:CO • KYG393421030

Current stock price

2.9876 USD
+0.77 (+34.58%)
At close:
2.925 USD
-0.06 (-2.1%)
Pre-Market:

This CO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CO Profitability Analysis

1.1 Basic Checks

  • In the past year CO was profitable.
CO Yearly Net Income VS EBIT VS OCF VS FCFCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

1.2 Ratios

Industry RankSector Rank
ROA 5.87%
ROE 10.27%
ROIC 6.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CO Yearly ROA, ROE, ROICCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2 4 6 8 10

1.3 Margins

Industry RankSector Rank
OM 48.97%
PM (TTM) 40.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CO Yearly Profit, Operating, Gross MarginsCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CO Health Analysis

2.1 Basic Checks

  • CO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, CO has about the same amount of shares outstanding.
  • There is no outstanding debt for CO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CO Yearly Shares OutstandingCO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
CO Yearly Total Debt VS Total AssetsCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 2.21 indicates that CO is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • CO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACC0.73
WACC8.75%
CO Yearly LT Debt VS Equity VS FCFCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 10.73 indicates that CO has no problem at all paying its short term obligations.
  • A Quick Ratio of 10.66 indicates that CO has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 10.73
Quick Ratio 10.66
CO Yearly Current Assets VS Current LiabilitesCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. CO Growth Analysis

3.1 Past

  • The earnings per share for CO have decreased by -1.41% in the last year.
  • CO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.71% yearly.
  • The Revenue has been growing slightly by 7.21% in the past year.
  • CO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.34% yearly.
EPS 1Y (TTM)-1.41%
EPS 3Y8.03%
EPS 5Y7.71%
EPS Q2Q%-18%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y8%
Revenue growth 5Y10.34%
Sales Q2Q%-1.69%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CO Yearly Revenue VS EstimatesCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B
CO Yearly EPS VS EstimatesCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. CO Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 5.15, the valuation of CO can be described as very cheap.
  • CO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.23.
Industry RankSector Rank
PE 5.15
Fwd PE N/A
CO Price Earnings VS Forward Price EarningsCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -5.81
CO Per share dataCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.67
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CO Dividend Analysis

5.1 Amount

  • CO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CO Fundamentals: All Metrics, Ratios and Statistics

Global Cord Blood Corporation

NYSE:CO (9/23/2022, 8:04:01 PM)

Premarket: 2.925 -0.06 (-2.1%)

2.9876

+0.77 (+34.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-15
Earnings (Next)10-11
Inst Owners0.03%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap400.08M
Revenue(TTM)1.24B
Net Income(TTM)501.06M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.15
Fwd PE N/A
P/S 2.29
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB N/A
EV/EBITDA -5.81
EPS(TTM)0.58
EY19.41%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.3
BVpS5.12
TBVpSN/A
PEG (NY)N/A
PEG (5Y)0.67
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 5.87%
ROE 10.27%
ROCE N/A
ROIC 6.39%
ROICexc N/A
ROICexgc 6.46%
OM 48.97%
PM (TTM) 40.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.73
Quick Ratio 10.66
Altman-Z 2.21
F-Score6
WACC8.75%
ROIC/WACC0.73
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.41%
EPS 3Y8.03%
EPS 5Y7.71%
EPS Q2Q%-18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.21%
Revenue growth 3Y8%
Revenue growth 5Y10.34%
Sales Q2Q%-1.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Global Cord Blood Corporation / CO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Global Cord Blood Corporation (CO) stock?

ChartMill assigns a fundamental rating of 6 / 10 to CO.


Can you provide the valuation status for Global Cord Blood Corporation?

ChartMill assigns a valuation rating of 9 / 10 to Global Cord Blood Corporation (CO). This can be considered as Undervalued.


Can you provide the profitability details for Global Cord Blood Corporation?

Global Cord Blood Corporation (CO) has a profitability rating of 5 / 10.


What is the valuation of Global Cord Blood Corporation based on its PE and PB ratios?

The Price/Earnings (PE) ratio for Global Cord Blood Corporation (CO) is 5.15 and the Price/Book (PB) ratio is 0.58.